Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies

MLA

Ronald R Bowsher, et al. “Similar Immunogenicity Profiles between the Proposed Biosimilar MYL-1501D and Reference Insulin Glargine in Patients with Diabetes Mellitus: The Phase 3 INSTRIDE 1 and INSTRIDE 2 Studies.” BMC Endocrine Disorders, vol. 21, no. 1, June 2021, pp. 1–10. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....462494f86002b679d45e3482b3a5cb83&authtype=sso&custid=ns315887.

APA

Ronald R Bowsher, Divya Pathak, Patrick Aubonnet, Charles Donnelly, Vinit S. Waichale, Bin Sun, Yaron Raiter, Abhijit Barve, Anita Rao, Shilpa G Ramaswamy, Nilanjan Sengupta, & Arnab Sinha Roy. (2021). Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies. BMC Endocrine Disorders, 21(1), 1–10.

Chicago

Ronald R Bowsher, Divya Pathak, Patrick Aubonnet, Charles Donnelly, Vinit S. Waichale, Bin Sun, Yaron Raiter, et al. 2021. “Similar Immunogenicity Profiles between the Proposed Biosimilar MYL-1501D and Reference Insulin Glargine in Patients with Diabetes Mellitus: The Phase 3 INSTRIDE 1 and INSTRIDE 2 Studies.” BMC Endocrine Disorders 21 (1): 1–10. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....462494f86002b679d45e3482b3a5cb83&authtype=sso&custid=ns315887.